Gilead Sciences to Release Second Quarter 2011 Financial Results on Tuesday, July 26, 2011

Conference Call and Webcast to Follow

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its second quarter 2011 financial results will be released on Tuesday, July 26, 2011, at 4:05 p.m. Eastern Time. At 5:00 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2011 and provide a general business update. The conference call will be accessible via the internet from the company’s website.

To access the webcast link, log on to www.gilead.com. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 1-800-299-7089 (U.S.) or 1-617-801-9714 (international) and dial the participant passcode 36874698 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, July 29, 2011. To access the replay, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 45716316. The webcast will be archived on www.gilead.com for one year.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).



CONTACT:

Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715
Investor Relations

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.